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Inflammatory bowel disease, a chronic relapsing-remitting disorder, affects three million 
adults in the United States. One of the main therapeutic goals in patients with inflammatory 
bowel disease is mucosal healing, measured by endoscopy, an invasive procedure that does not 
always reflect patient symptomatology. To address these limitations, clinicians have developed 
patient-reported outcome measures, questionnaires evaluating bowel symptoms and quality of 
life. However, the clinical utility of these patient-reported outcome measures and their 
correlation to objective markers of inflammation is unclear. We will determine the efficacy of 
using a patient-reported outcome measure to inform treatment for inflammatory bowel 
disease. In a randomized clinical trial, we will compare disease metrics of patients receiving 
treatment guided by a patient-reported outcome measure compared to those of patients receiving 
standard treatment. This study will confirm the utility of patient-reported outcome measures, 






Chapter 1: Introduction 
1.1 Background 
 Patients with inflammatory bowel disease face significant detriments in health-related 
quality of life (HRQL) and experience varied symptoms including depression, anxiety, and 
fatigue. Existing clinical measures to monitor disease activity often fail to evaluate these 
significant components of the chronic condition. This study proposes a randomized clinical trial 
to test the use of a patient-reported outcome measure (versus standard of care) on increasing 
quality of life for patients with IBD in an outpatient clinic setting over the course of six months.  
Inflammatory Bowel Disease and Current Disease Monitoring 
Inflammatory bowel disease (IBD) refers to a group of chronic relapsing-remitting 
diseases including ulcerative colitis (UC) and Crohn’s disease (CD). Inducing and maintaining 
clinical remission is the ultimate goal of therapy. In addition, the therapeutic targets of IBD have 
now evolved beyond clinical remission to include mucosal healing. Mucosal healing refers to the 
resolution of ulcerations on endoscopic evaluation. Mucosal healing has been associated with 
favorable outcomes such as decreased rates of hospitalization, surgery, and perianal 
complications, as well as improvement in quality of life and increased work productivity.1-3 
Unfortunately, previous studies have demonstrated a lack of association between mucosal 
healing and symptomatology, like those measured by Crohn’s Disease Activity Index (CDAI).4,5 
Therefore, the current gold standard for evaluating mucosal healing is endoscopy or imaging for 
isolated small bowel disease. Unfortunately, endoscopy is not only invasive to perform on 
patients on a routine basis, but also costly and time-consuming for patients and providers.6-8 
Therefore, clinicians continue to search for a reliable measure of clinical activity that also 
predicts mucosal healing. 
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Due to the invasive nature and cost of endoscopy, practitioners often have to rely on other 
indirect measures of inflammation such as biomarkers. One non-invasive inflammatory marker is 
C-reactive protein (CRP), a protein produced by the liver in response to inflammation with a 
half-life of only 19 hours. Although non-invasive, quick, inexpensive, and commonly ordered by 
clinicians, CRP levels may be affected by many factors including genetics, smoking, or obesity 
and may be falsely elevated in trauma, infection, cardiovascular events, neoplasia, or 
extraintestinal inflammation. Additionally, about one quarter of IBD patients have a genetic 
single nucleotide polymorphism (SNP) in a CRP gene which results in CRP never being elevated 
even in the setting of active inflammation.9 Furthermore, although one meta-analysis found CRP 
to have a high specificity of 0.92 when correlated with endoscopic measures of disease activity, 
its sensitivity was only 0.49. Results of CRP must be interpreted with caution given this high 
proportion of falsely negative results.10  
         Another non-invasive marker of inflammation is fecal calprotectin (FCP). Calprotectin is 
a calcium binding protein found in the cytosol of neutrophils; thus FCP levels are directly 
proportional to inflammatory migration of neutrophils to the gastrointestinal tract.7,9 FCP may be 
falsely elevated in other gastrointestinal disorders such as infection, malignancies, or medication 
use such as NSAIDs. FCP measurements are also often not covered by insurance and thus 
expensive for patients.9 
         Clinicians and researchers use standardized scoring systems to incorporate data findings 
into more objective and quantitative measures of disease activity. The most commonly used 
clinical scoring systems are the Mayo Clinic Score for UC (Mayo-UC) and the Crohn’s Disease 
Activity Index (CDAI) for CD.11 Unfortunately, both instruments have limitations. The Mayo 
Clinic Score is composed of subjective questions completed by clinicians and does not always 
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correspond with a patient’s own perceptions of their disease activity.12 The CDAI does not 
always correlate well with endoscopy scores and may be falsely elevated in the presence of other 
gastrointestinal diseases.13-16 Additionally, even in clinical trials, definitions of disease activity 
vary across studies, making the data difficult to compare and incorporate into practice.14,15 These 
composite measures of disease activity are time-consuming to collect, lack correlation with 
endoscopic findings, and leave out the patient’s perception of disease.17 
Inflammatory Bowel Disease & Health-Related Quality of Life 
In addition to the aforementioned shortcomings, current disease activity indices do not 
take into account comorbidities such as depression, anxiety, fatigue, and quality of life 
impairment which are downstream effects of initial bowel inflammation. A majority of IBD 
patients must contend with these symptoms, and they are often of utmost importance to 
patients.11 As IBD is often diagnosed at an early age, these extraintestinal manifestations of the 
disease can be devastating to patients, and can lead to a cyclical process of pathology. For 
example, sleep disturbances have been linked to worsening pain and fatigue in patients with 
chronic inflammatory conditions.18 Finally, the chronic nature and potential complications of 
IBD and the lack of a definitive cure have been shown to contribute to depression in patients, 
overall reducing HRQL.19 
In order to promote patient quality of life, it is essential that providers monitor these 
symptoms. Current disease monitoring tools do not account for these symptoms, instead focusing 
on bowel inflammation. In order to promote optimal patient outcomes there is a need for a 
clinically practical tool to ensure these symptoms are monitored and addressed for all patients 
with IBD.  
Patient-Provider Relationship 
 4 
 With any chronic disease, the foundation of effective disease management is the 
relationship between patient and provider. This is especially true in the care of IBD, as patients 
must face significant stigma surrounding their physiological symptoms, contend with the lack of 
a definitive cure for the disorder, manage treatment side effects, and cope with a myriad of 
psychological effects of the disease. Unfortunately, the rate of addressing these important 
concerns is low in IBD care. For example, surveys have shown nearly half of gastroenterologists 
fail to discuss quality of life with their patients.20 In a more recent qualitative study, despite 78% 
of patients endorsing that the disorder negatively impacts their quality of life, only 45% of these 
patients discussed this fact with their provider, and a further 23% minimized these negative 
effects.21 Additionally, providers underrate both patient symptoms and the effect of these 
symptoms on patients’ quality of life.22 This lack of communication leads to worse outcomes 
including increased levels of patient anxiety and decreased adherence to disease therapeutics.23-25 
Psychological stress has been shown to correlate with increased symptomatology and relapse in 
IBD.26 Furthermore, causative factors in medication nonadherence include patient and physician 
discordance as well as a lack of trust in providers.27 
 These deficits in communication may persist as providers plan treatment options for 
patients. Research has shown that providers and their patients have diverging views when it 
comes to treatment goals. Patients generally aimed for symptomatic remission with significant 
improvements in the quality of their lives, whereas provider targets tended to be focused on 
objective disease remission or a reduction in other objective markers of inflammation.28 There is 
now a shift in the culture of medicine towards more patient-centered care, and an integral part of 
this transformation will be empowering patients to be involved in the management of their 
diseases. In one survey, 98% of IBD patients reported that it was “very important” or “quite 
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important” to be part of the decision-making process with their providers.29 Clinicians must 
create opportunities to discuss health-related quality of life in order to foster a trusting 
relationship with patients and empower them as goal setters in disease management, which will 
ultimately improve patient outcomes. 
The Promise of Patient-Reported Outcome Measures 
In response to the limitations of current disease indices, the FDA called for the 
production and use of patient-reported outcome measures (PROMs) in both clinical practice and 
research trials in 2006.30  PROMs are useful tools since they elicit subjective symptom 
information, such as pain intensity and relief, and remove the need for interpretation from a third 
party. PROMs provide the opportunity to improve patient-provider communication, improve 
accuracy of symptom assessment, and ultimately aid patient education and self-
management.31  Additionally, PROMs introduce the opportunity for a review of symptoms that 
are secondary to a main diagnosis. A driving force behind utilizing PROMs in IBD therapies is 
promotion of a “co-production” model of care, where patient needs are integrated into clinical 
decision-making to ultimately create the best outcome. PROMs create the opportunity for 
interdisciplinary care by standardizing factors of care either within a specialty or outside of that 
specialty.11 In addition, another incentive for the use of PROMs is to maintain control over 
patient symptoms to ensure they remain in remission.32 Finally, many PROMs also incorporate 
questions regarding a patient’s mental health and fatigue symptoms which has the promise of 
improving patient health-related quality of life.  
PROMs have been shown to be effective when used in the care of a variety of conditions. 
One randomized control trial demonstrated the utility and benefit of these measures in an 
oncology setting where the use of an electronic PROM resulted in improved health related 
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quality of life and reduced hospitalizations.33 It is important for these tools to be tailored to 
specific conditions, such as in the case of the Phenylketonuria impact and treatment Quality of 
Life Questionnaire (PKU-QOL), which allows providers to monitor important factors specific to 
individuals with metabolic conditions such as dietary protein restrictions.34 An analysis of 
existing PROMs by Greenhalgh et al. found that the completion of PROMs enabled a patient to 
bring up specific symptoms to their provider, since the process of completing the questionnaire 
allowed for patients to reflect on their health and ultimately recall minute details about their 
condition.35 PROMs have become mandated for patients undergoing certain elective surgical 
procedures in the United Kingdom. These PROMs collect data about health satisfaction and 
other metrics in the NHS, allowing for continued quality improvement efforts.36 Another 
research study in an oncology clinic incorporated PROMs into routine practice and resulted in 
increased survival with those with metastatic cancer compared to usual care.37 The application of 
PROMs has many evident benefits, many of which would be applicable to IBD once an 
appropriate measure is found to be valid, efficacious and efficient in routine IBD care. 
Specific IBD Related Patient-Reported Outcome Measures 
There is currently a need for a PROM in IBD that is both feasible for routine clinical use 
and accurately predicts objective measures of inflammation such as mucosal healing. One 
potential tool is the 13 item IBD-Control Questionnaire (IBD-CQ). This questionnaire was 
designed for use in clinical settings to assess four core domains of IBD control: physical 
symptoms, social impact, emotional impact, and treatment efficacy. Patients with IBD were 
directly involved in the development of each item of the questionnaire and it takes just over a 
minute to complete.38 The questionnaire has demonstrated utility in a variety of clinical settings 
evidenced by its successful use in recent studies to monitor IBD care in the National Health 
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System of the UK, determine the prevalence of IBD in Iran, and evaluate the utility of a web-
based ulcerative colitis program.39-41 
The National Institute of Health (NIH) developed another such tool in 2005, the Patient-
Reported Outcome Measurement Information System (PROMIS), for use in patients with a 
variety of chronic disorders. The PROMIS questionnaires are designed to provide standardized 
information and assess many domains including physical health (function and symptoms), 
mental health (emotional distress, cognitive function, and positive psychological functioning), 
and social health (role participation and social support). The PROMIS questionnaires have been 
used effectively in research studies, clinical practice, and policy development across a variety of 
diseases.42 
 
1.2 Statement of the Problem 
 Current strategies to monitor patients with IBD are invasive, costly, and do not capture 
common patient symptomatology such as fatigue and mental health issues. PROMs have the 
potential to address these gaps; however, there is a significant lack of research evaluating these 
measurement tools. Currently, few clinical practices utilize standardized PROMs for various 
reasons from administrative costs and training to the reluctance to move away from conventional 
patient interviewing methods.11  Furthermore, some PROMs require specialized technology that 
is not readily available to all providers. Also, certain PROMs have issues with interpretability, 
which may make providers reluctant to utilize them. Finally, some providers are hesitant to 
utilize PROMs since they feel as though the questions may be too intrusive and damage the 
patient-clinician relationship.43 A thorough randomized controlled clinical trial is required to 
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confirm the efficacy and validity of specific IBD patient-reported outcome measures, which 
would ultimately result in their implementation into clinical practice. 
Additionally, a successful study would confirm the validity of the IBD-CQ and PROMIS 
questionnaires by determining whether these PROM scores correlate to objective measures of 
inflammation such as mucosal healing as measured by endoscopy. In one review of PROMs 
currently available for use in the IBD population, only six have been validated using findings 
from endoscopy. Additionally, the measures showed only moderate accuracy when used to 
predict disease activity with an area under the curve for correct classification ranging from 0.63 
to 0.82. Finally, some PROMs only contain one question about ongoing disease activity, a factor 
that may be an issue since IBD has a multifactorial disease process.8 
As a chronic relapsing disease with peak incidence of early thirties, the prevalence of 
IBD is rising dramatically as the population ages. IBD care is currently estimated to cost 
anywhere from $14 to $31 billion in the United States. As the population of patients with IBD 
rises, their care must redirect its aims to become more efficient and patient-centered.44 PROMs 
will be instrumental in this transition to value-based care, but require further research to ensure 
that these measures are effective when used routinely and meet all required validity criteria. 
Additionally, there are many other factors needed for the effective implementation of these 
measurement tools. Ease of administration, a short time interval between patient outcome and 
time of reporting, and good reliability are key items needed for a PROM to be effective in 
clinical practice.8 Ideally, PROMs should support decision-making for each individual patient, 
and also be able to be used in clinical trials in order to seamlessly link research to actual 
practice.17 Investigating the efficacy and validity of the IBD-CQ and PROMIS questionnaires in 
the management of IBD will be a precursor to creating an environment of patient-centered care. 
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PROMs create the opportunity to evaluate a patient’s symptomatology holistically. The inclusion 
of questions about mental health and fatigue extends evaluation beyond the current guidelines of 
mucosal healing to include other aspects of a patient's health-related quality of life.  
 
1.3 Goals and Objectives 
 The proposed study’s goal is to determine the efficacy of utilizing a clinically practical 
PROM, the IBD Control Questionnaire and the PROMIS questionnaires, to individualize disease 
monitoring and treatment decisions for adult patients with IBD. A secondary aim is to confirm 
the validity of the aforementioned PROMs by correlating scores to objective measures of 
inflammation such as mucosal healing as measured by endoscopy over a six-month period. The 
primary study outcome will be global health-related quality of life as measured by the EuroQol 
questionnaire (EQ-5D-5L). This questionnaire is both reliable and validated as a measure of 
patients’ quality of life and is commonly used in research.45 This outcome will speak to the 
efficacy of using PROMs to individualize treatment of IBD. 
 Secondary outcomes will include patient disease activity as measured by endoscopic 
scores (Mayo UC, CDAI), discussion of HRQL in the clinic visit, rate of disease exacerbations, 
patient and provider satisfaction, cost of treatment, and non-invasive biomarkers of inflammation 
(fecal calprotectin, erythrocyte sedimentation rate, albumin, c-reactive protein). This information 
will inform clinical monitoring methods for patients with IBD. Additionally, this information 
will be used to determine the extent to which the IBD-CQ aligns with traditional measures of 
disease activity (Mayo UC, CDAI, lab markers) and psychosocial domains (depression, anxiety, 
fatigue, social functioning). Furthermore, we will determine the IBD-CQ’s ability to detect 
clinically important changes in patient symptomatology after six months of treatment. Both the 
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primary and secondary outcomes resulting from the proposed study will provide guidelines to 
promote both patient centered care and holistic disease management.  
 
1.4 Hypothesis 
We hypothesize that of 258 adult patients with IBD, those who receive individualized 
treatment as structured by a PROM will have a statistically significant difference in health-
related quality of life as measured by the EuroQoL questionnaire (EQ-5D-5L) as compared to 
those receiving standard clinical care after a six month period. 
Definitions 
• Intervention: Patients will complete a PROM (IBD-CQ and PROMIS) prior to their initial 
evaluation appointment. The clinician will receive the results of the PROM and subscores 
and use this information to discuss treatment during the visit. Six months later, this will 
be repeated at another clinic visit.  
• Standard of Care: Designed using evidence-based practice, the standard of care will 
include a thorough baseline exam, a therapy plan based on current guidelines, clinic and 
phone call follow-up as needed, as well as information sheets provided about the 
disease.46-48 Control participants will complete the same PROM (IBD-CQ and PROMIS) 
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Chapter Two: Review of the Literature 
2.1 Introduction 
A detailed review of the literature was performed of references published from January 
2000 through April 2020 using a variety of sources, including Ovid (Medline), Pubmed, 
ScienceDirect, CINAHL, and Cochrane Medical Library. Only English-language articles were 
included in the review. Selection of articles included within this literature review began with 
screening study titles and abstracts followed by full text examination of articles to evaluate their 
relevance to the proposed research study. The following terms were implemented in the search 
for pertinent literature related to IBD and PROMs in all of the above databases: patient-reported 
outcome measure (patient reported outcome measures, patient reported outcome measurement, 
PROM, patient reported outcome, PRO, patient reported measure, patient reported measures, 
patient centered outcome measure, patient centered outcome measures, PCOM, routine outcome 
monitoring, clinical feedback, quality of life, health-related quality of life, HRQL, HRQOL, self-
reported outcome, self-reported outcomes), and inflammatory bowel disease (inflammatory 
bowel diseases, ulcerative colitis, Crohn’s disease). To date, no randomized clinical trials have 
been conducted that directly evaluate the routine use of PROMs in IBD, so the review was 
expanded to include the use of PROMs in other diseases, as a thorough review of previous 
methodology in other diseases is necessary to compose a properly investigated study. We also 
examined the reference lists from all of the eligible studies and literature reviews on the subject 
to identify additional relevant material. Additional key terms were implemented to search for 
protocol-specific information: parallel study design, confounders (confounding variables), 
statistical analysis, and limitations (drawbacks, issues, flaws, defects). 
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2.2 Current Burden and Disease Monitoring of Inflammatory Bowel Disease 
More than three million adults in North America currently live with inflammatory bowel 
disease (IBD).1 This estimate is expected to rise to four million in just the next decade.2 As IBD 
is a chronic relapsing-remitting disease, clinicians must regularly monitor disease activity in 
patients. Clinical remission, which refers to absence of symptoms is one of the main goals of 
IBD treatment. The therapeutic targets of IBD, however, have evolved beyond clinical remission 
to include objective evidence and measures of inflammation. One such target is mucosal healing 
which refers to resolution of ulcerations seen on endoscopy. The gold standard used to assess 
disease activity is endoscopic evaluation of mucosal inflammation.3 Unfortunately, endoscopy is 
not only invasive to perform on patients on a routine basis, but also costly and time-consuming 
for patients and providers.3-5 Furthermore, mucosal healing on endoscopy does not always align 
with clinical remission in patients. Researchers in one study performed endoscopy on 127 
patients with IBD who had been in clinical remission for at least one year, and 65% of these 
patients showed mucosal inflammation indicative of active disease.6 In a second study of patients 
with CD, over half of patients continued to show inflammation on endoscopy or biomarkers 
despite having achieved clinical remission, and about one fifth of patients continued to be 
symptomatic despite a lack of evidence of inflammation on endoscopy or biomarkers.7 
         Clinicians and researchers use standardized scoring systems to incorporate data findings 
into a more objective and quantitative measure of disease activity. The most commonly used 
clinical scoring systems are the Mayo Clinic Score for UC and the Crohn’s Disease Activity 
Index (CDAI) for CD.8 Despite their widespread use in clinical practice as well as research 
studies, both metrics are insufficient due to subjective questions, lack of patient perspective, and 
lack of correlation with endoscopy.9-13 Additionally, these indices do not measure symptoms that 
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are often most important to patients: depression, anxiety, fatigue, and quality of life impairment.8 
Finally, even in clinical trials, definitions of disease activity vary across studies, making the data 
difficult to compare and incorporate into practice.12-14 These composite measures of disease 
activity are time-consuming, lack correlation with endoscopic activity, and leave out a patient’s 
perception of disease causing strain in the patient-provider relationship.15 
 
2.3 Clinical Promise of Patient-Reported Outcome Measures in Inflammatory Bowel 
Disease 
In order to combat the drawbacks of current disease monitoring techniques, the FDA 
began to promote patient-reported outcome measures in 2006 and clinicians have followed 
suit.16  These disease monitoring tools are exceptionally useful, as they display subjective 
symptom information directly from the patient, such as pain intensity and fatigue, without 
necessitating interpretation by a clinician or others. The utilization of PROMs in the care of 
IBD will empower patients to become “co-producers” of care and treatment of their disease. 
Additionally, PROMs standardize outcomes across disciplines in clinical research. This enables 
both incorporation of clinical research into practice, as well as continuity across various 
specialties.8 Additionally, continual use of PROMs facilitates self-monitoring of patients’ 
condition over time, tracking both disease stability and exacerbations.17  
         Despite the demand from practitioners and researchers to use PROMs in IBD, there is a 
lack of research regarding the efficacy of routine use of these measures in IBD clinical practice. 
Additionally, few PROMs have demonstrated validity in the IBD patient population. In one 
review of twenty different measures, only six have been validated using findings from 
endoscopy.4 Additionally, the measures showed only moderate accuracy when used to predict 
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patient mucosal inflammation with an area under the curve for correct classification ranging 
from 0.63 to 0.82. None of the reviewed PROMs have met the FDA criteria for validity, which 
recommend evaluating content validity, construct validity, criterion validity, reliability, and 
responsiveness to change. Finally, some PROMs only contain one question about ongoing 
disease activity, a factor that may be an issue since IBD has a multifactorial disease process.4  
A variety of these IBD-specific PROMs have been detailed in Table 1. These six tools 
differ with regards to reliability, validity, and responsiveness to change, but show some 
similarity in the outcomes they measure. For example, the IBDQ-32, IBDQ-9, SIBDQ, and 
EIBDQ all evaluate a patient’s quality of life. The best established of these tools is the IBDQ-
32.18 Despite its demonstrated utility in research settings, this PROM has failed to be utilized in 
clinical practice due to its lengthiness which inconveniences patients, and also its licensing 
requirement which deters providers.19 In contrast, the IBD-CQ looks at outcomes of physical, 
social, emotional, and treatment response, and this tool ranks highest when considering 
reliability, validity, and responsiveness to change.19 This thirteen-item metric assesses four core 
domains of IBD including physical symptoms, social impact, emotional impact, and treatment 
efficacy. The time of completion is roughly one minute, and the IBD-CQ does not require a 
license to be utilized.20 Not only is the IBD-CQ simple to complete, but the results are also easily 
interpreted, and it has been proven to be effective in clinical settings based on studies set in the 
UK and Iran.21,22 
Table 1. Inflammatory bowel disease specific patient-reported outcome measures 














High Medium High Medium Medium 
 18 










































High High High High High 
 
Chart includes instruments that evaluate patient functioning or quality of life.19,23 
Non-disease-specific PROMs which show great promise for use in the IBD patient 
population include the PROMIS system and the EQ-5D-5L. Launched by an initiative from the 
NIH in 2004, the Patient Reported Outcomes Measurement Information System (PROMIS) is a 
database of patient-centered tools that can be used to measure the physical and mental health of 
individuals.24 These measurement tools are a result of the thrust to incorporate patient 
experiences into care in order to focus treatment and promote shared decision-making.25 
Additionally, patient experiences are more often being used to evaluate outcomes rather than 
solely relying on diagnostic information. The items of focus within the database are based on 
domains of interest, rather than specific disease processes, meaning they look at health factors 
such as pain, anxiety, or peer relationships.26 The questionnaires from the PROMIS system have 
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been implemented in a variety of clinical settings, from gynecologic oncology to total shoulder 
arthroplasty.27 Within the setting of IBD, questionnaires from the PROMIS database have been 
validated and implemented within clinical research for this population.28-30 The PROMIS system 
has provided many useful tools for providers around the world to better understand their patients’ 
experiences. A second non-disease specific PROM that has potential for use in the IBD 
population is the EQ-5D-5L. Developed in the late 1980s, the EQ-5D-5L is an internationally 
used instrument that has the capability to measure health-related quality of life. By observing the 
five dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, 
the tool can differentiate between clinically important differences in health-related quality of life 
between individuals within a specific disease population.31 The EQ-5D-5L has been successfully 
used as an outcome measure in other studies evaluating the routine use of PROMs in certain 
disease populations.32 Furthermore, within the context of IBD, this tool has shown to be valid, 
reliable, and responsive.33,34 
IBD is a chronic disease that often manifests when patients are in their early thirties and 
has been displaying a dramatic increase in prevalence as the population ages. The financial 
burden of IBD is considered to be between $14 to $31 billion in the United States each year, and 
there are significant demands to modify disease management towards effective and economical 
patient-centered care.35 PROMs will be of utmost importance to pivot towards this value-based 
care, yet there is a significant lack of these measurement tools that fully meet the validity criteria. 
Optimally, PROMs will be integral to the decision-making process for the individualized 
treatment of each patient.15 Empowering patients and integrating their perspectives into a 
treatment process will provide an unparalleled advantage for IBD care as well as the care of 
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other chronic conditions. Since these tools directly measure patient perspective, they will prove 
to be invaluable to both the PA practice and the medical field at large. 
 
2.4 Clinical Promise of Patient-Reported Outcome Measures in Other Diseases 
The literature on the benefits of using PROMs in routine clinical practice in other 
diseases is abundant. Their use has been studied in a variety of chronic conditions such as 
cancer,36-38 chronic kidney disease,39 mental health disorders,40-42 multiple sclerosis,43 
rheumatoid arthritis,44 among others. There has been significant research and integration of 
PROMs into routine practice with regards to treatment and management of cancer symptoms, as 
PROMs ensure patients’ experiences and perspectives are involved in health outcome 
measurement when evaluating clinical research or when assessing quality of care in real world 
clinical practice.45 One study researching patients with cirrhosis found 88% of providers found 
PROMs helpful in commencing patient treatment and counseling for specific symptoms. The 
same study showed 91% of the sample patient population found PROMs effective in 
communicating emotional and physical treatment needs to their providers.46 In qualitative 
literature on the management of patients with non-malignant pain, providers felt PROMs made 
important contributions to the clinician-patient interaction, allowing for better goal setting and 
individualization of treatment.47-49 Aside from chronic conditions, PROMs have also 
demonstrated the potential for clinical improvement in surgical subspecialties, exemplified in the 
United Kingdom with the National Health Service’s program to collect PROs for hip and knee 
replacements, as well as groin hernia and varicose vein surgeries.27 Additionally, many disease 
advocacy groups have championed the utilization of PROMs in disease management.50 In 
summary, ample evidence suggests that weaving these instruments into routine clinical practice 
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to glean data on patients’ perspectives will positively impact their outcomes via improving 
patient-provider interaction, communication, and shared decision-making.51  
Furthermore, some research has gone beyond exploring the use of PROMs in improving 
the patient-provider relationship to their use in improving overall patient outcomes. One research 
study examined the use of a PROM during three outpatient clinic visits versus usual care for 
adolescent patients with Type 1 Diabetes Mellitus. After the three visits, those in the intervention 
group reported significant improvement in self-esteem and mental health, increased participation 
in family activities, and fewer behavioral problems as compared to those in the control group.52 
Another study examined the impact of PROMs for patients with advanced solid tumors receiving 
routine chemotherapy and found that the intervention group had an increase in health related 
quality of life as compared to the control cohort. Furthermore, patients in the intervention group 
were less frequently admitted to the emergency room or hospitalized during the study as 
compared to the control group, as the measurement tool was often able to pick-up on secondary 
symptoms of advanced cancer that often go undetected.32 These studies confirm that the 
improved patient-provider communication found with the use of PROMs leads to a subsequent 
beneficial impact on patient outcomes. 
 
2.5 Review of Relevant Methodology 
Study Design Approaches and Possible Confounders 
 Most of the published trials evaluating the routine use of PROMs in clinical practice 
utilized parallel study designs,32,37,38,40,52-70 but a minority of the trials did use crossover 
designs.71,72 Parallel study designs are most commonly used in clinical research as they are both 
simple and feasible to complete.73 In this design, patients are randomized to a study arm and will 
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stay in that assigned treatment arm for the duration of the research study.74  In contrast, crossover 
designs, often used when investigating a non-curative and symptomatic treatment for a chronic 
illness, have many advantages. The chief advantage is the reduction of confounding bias in the 
study, as each crossover patient is his or her own control.75 Unfortunately this advantage also 
leads to the design’s major limitation: the effect of the order of intervention.76 Receiving the 
intervention initially versus after the control intervention or vice versa may have a significant 
effect on participant outcomes.77 Additionally, crossover trials require long periods of study 
participation.78 As many of the trials assessed have a limitation of attrition to begin with, this 
added study time runs the risk of introducing additional selection bias and compromising data of 
the proposed study.57,70,79 Finally, due to its relapsing-remitting nature, studying inflammatory 
bowel disease with the crossover design might not be ideal. Crossover study designs require that 
participants’ disease states will be stable and return to baseline between trial periods, which may 
not occur in IBD.80 In conclusion, the use of a parallel study design will be optimal in this 
clinical investigation as it will avoid the carryover effect of multiple interventions, reduce the 
length of subject participation, and is most appropriate to evaluate the patient population. 
 A thorough randomization process will be necessary to mitigate any possible 
confounding factors when employing a parallel study design. Randomization of study 
participants will minimize the effect of any confounding from age, sex, diagnosis (UC vs. CD), 
disease severity or activity, disease location, duration of disease, comorbidities, type of medical 
therapy, and socioeconomic factors. Previous studies with PROMs and other diseases controlled 
for covariates such as age, sex, race, and education level.32,37,43,55,57,59,61,67,79 Trials specific to the 
population of patients with IBD controlled for gender, age, and disease type.81,82 Confounding 
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will be minimized by employing a rigorous randomization protocol in our proposed research 
study.  
Primary and Secondary Outcomes 
Literature Review of Outcomes 
 There are a variety of outcomes measured and reported in the PROM research literature 
which are often grouped into three main categories.83-86 The first category relates to delivery of 
clinical services, including the number of symptoms addressed by providers,38,57,59,63,69,79 referral 
to outside resources,42,72 discussion of health-related quality of life during clinic visit,53,58,72 and 
documentation in the patient’s medical chart.58,64 Changes in the delivery of clinical services are 
cited as the most proximal outcomes, demonstrating changes in patient-provider communication, 
which will have downstream effects on patient outcomes.87,88 
The second category of outcomes is change in patient health status, such as patient 
functioning,65,68 quality of life,32,41,52,57,68-70,72,79 number of emergency visits,32,66 symptom 
distress,38,40 and other symptomatology.37,55,56,61-64,89 These changes in patient health outcomes 
are more distal to the intervention, downstream from changes to the patient-provider interaction 
and treatment decisions. The specific outcome of health-related quality of life has demonstrated 
statistically significant change after intervention in a variety of patient populations.32,41,52 In most 
of the studies where this outcome has not been statistically significant, it has still demonstrated a 
positive trend.68,70,79 Non-significant results could be due to a number of limitations in the 
referenced studies including high rates of attrition,57,70,79 poor adherence to the intervention and 
missing data,57,79 lack of education for providers regarding the use of the PROM,70 poor 
standardization of the intervention,69 lack of communication of results to the treating 
provider,57,69 priming the treating provider towards discussing quality of care in all treatment 
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visits,79 insufficient power,57,68,69 and finally a short length of intervention and time to follow-
up.68 
The third outcome category was a general assessment of satisfaction with the quality of 
care, including the perceived utility of the PROM by the provider53,54,62,70,72,79 or the 
patient,32,41,52,54,57,58,61,62,64,67,69-72,79,89 or the cost-effectiveness of the intervention.65  
A majority of primary outcomes in the literature assessed changes in patients’ health 
status including HRQL32,41,52,57,68-70,79 and specific patient symptomatology.37,55,56,61-64,89 Many of 
the research papers reviewed used patient-physician communication measures as a primary 
outcome measure, such as discussion of quality of life during the clinic appointment53,58,72 or the 
number of symptoms addressed in the appointment or in the medical record.38,59,79 Still fewer 
used a primary outcome measure of satisfaction.54,58,67 
Selected Outcomes for Research Proposal 
 For the purposes of our proposed intervention, we elected to use the primary outcome of 
change in patient health-related quality of life (HRQL) as measured by the EQ-5D-5L. With 
regards to secondary outcomes, we selected patient disease activity as measured by endoscopic 
scores (Mayo UC, CDAI), discussion of HRQL in the clinic visit, rate of disease exacerbations, 
patient and provider satisfaction, cost of treatment, and noninvasive biomarkers of disease 
activity (albumin, fecal calprotectin, CRP, ESR). As discussed earlier in the research proposal, 
the results of the PROM will also be assessed as to whether or not they correspond to disease 
activity and to measures of psychosocial domains, as well as the PROM’s responsiveness across 
the six-month interval. 
Study Population and Recruitment Approaches 
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Previous studies have included a variety of sample populations of patients with chronic 
conditions as these tools give providers information about patient symptomatology, functional 
capacity, and emotional status that are inaccessible from diagnostic tests alone.88,90 PROMs 
assess SPADE (sleep, pain, anxiety, depression, energy) symptoms as well as any other 
nonspecific symptoms that patients often fail to bring up to their provider.64 The relative 
anonymity of completing a PROM allows for the discretion of certain symptoms that carry 
significant stigma. For example, some clinicians have found that the implementation of PROMs 
enables frank conversations regarding sexual dysfunction, incontinence, and rectal bleeding in 
patients with prostate cancer, symptoms that were often downplayed or not discussed at all by 
patients prior to their use.91 PROMs are ideal to use in the care of IBD due to the prevalence of 
anxiety, depression, fatigue, and reduced quality of life, symptoms not commonly addressed by 
providers, but of utmost importance to patients.8,92 Furthermore, many of the symptoms involved 
in the condition carry significant stigma, which has the potential for interfering with patient-
provider communication, a factor circumvented by the use of PROMs.93 
Based on previous research, our recruitment approach will draw participants from a 
specialized inflammatory bowel disease gastroenterology outpatient clinic. This does have the 
potential limitation of selection bias, including only patients highly motivated and already 
connected to care. Since the proposed intervention would most benefit this select group of 
patients, this limitation is acceptable.  
Inclusion and Exclusion Criteria 
 Most of the research studies reviewed used minimal restrictions on study populations, 
making each study more generalizable and comparable to real-world clinical practice. Most 
studies restricted participation to adult patients with a specific disorder.53,55,56,61,65,66,68,69 Often 
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studies also required participants to have basic language proficiency,32,37,54,56,58,61,62,64,72,79,89 and 
excluded those unable to provide informed consent.37,56,57 A few studies listed an exclusion 
criteria of concurrently participating in any other HRQL studies, as there could potentially be a 
risk of contamination across different study interventions.32,72,79 In some interventions, the 
computerized delivery of the PROM necessitated inclusion criteria of basic computer 
literacy58,62,66 as well as exclusion criteria if the participant had no access to an email account.65 
Rarely studies excluded patients with other chronic medical issues that may influence the results 
of the PROM used.37 Studies that did so suffered from a large loss of external validity as the 
number of patients with multiple chronic conditions has been estimated to be from 20 to 30 
percent of the older population.94 
 Most of the reviewed interventions involving patients with IBD also restricted patient 
populations to adults with the disease diagnosis.92,95-98 Some studies used specific exclusion 
criteria regarding the location of disease or the presence of a stoma due to difficulty with 
assessing disease activity indices in these patients.92 Other studies confirmed the disease 
diagnosis with a central reader evaluating the patients’ endoscopic data.17,99 Some studies 
excluded patients with comorbidities of autoimmune diseases, infections, malignancies, small 
bowel obstruction, or ileostomy due to concerns that it could alter some of the laboratory 
assessments used in the study such as CRP or fecal calprotectin, resulting in limitations to the 
study’s real world applications.99 
 As IBD is a chronic condition with a patient population that has many comorbidities, it 
will be important to stringently define the inclusion and exclusion criteria in order to maximize 
both external and internal validity. The inclusion criteria of adults with a diagnosis of IBD with 
basic literacy are necessary when using a PROM as an intervention in our study population. 
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Additionally, patients with an inability to provide informed consent or who are participating in 
other clinical studies will be excluded due to ethical and internal validity reasons, respectively. In 
order to maximize the study’s generalizability and impact on clinical practice, exclusions to other 
comorbidities will not be used. Importantly, these few restrictions on patient eligibility criteria 
will enable our proposed study to feasibly recruit an adequate number of participants and make 
the results of our study generalizable to real world practice. 
Intervention 
 The reviewed literature varied in regard to design and implementation of the PROM 
intervention. Most researchers provided feedback to clinicians regarding the results of patients’ 
PROMs, but a few of the studies merely provided PROMs to patients without involving clinician 
feedback.56,57 Failing to disclose PROM results to clinicians greatly reduces their potential utility 
to influence patient-physician communication and thus patient outcomes. Physician notification 
of the results of patients’ PROMs is vital to our proposed intervention.  
The studies also varied in the amount of education provided to clinicians regarding the 
intervention, with some interventions providing no provider training at all.32,53,61,62,89 One recent 
literature review found no correlation between provider training and the success of a PROM 
intervention.83 Contrary to this finding, researchers suggest that clinicians fail to implement these 
measures into practice due to skepticism regarding the validity of the measures, misconceptions 
about the time required to administer the measures, and unfamiliarity or lack of knowledge about 
how to effectively use the data in clinical practice.49,100,101 Despite the mixed evidence in the 
literature that clinician education improves the implementation of the PROM in clinical practice, 
we believe this education will be necessary for the success of the intervention.  
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Finally, in a majority of the studies reviewed, the participants self-administered the 
PROM without the involvement of an interviewer, but a few studies involved telephone 
administration of the questions.61,70 The self-administration method aligns with the original intent 
of the PROM to provide patients’ perspectives, without the involvement of a clinician or third 
party, so this method will be used in our proposed intervention.16 Although most PROMs were 
paper questionnaires, some did provide electronic modes of completion32,38,58,70,71 which is more 
relevant to current practice as healthcare becomes more digitized, so this will be offered as an 
option in our research protocol.  
Sample Size 
 The PROM studies reviewed had a large range of participants, the smallest being n=4368 
and the largest being n=113455. Although not all studies reviewed reached statistical significance 
in outcome variables, this could be due to a variety of limitations in study designs as outlined in 
the “Primary and Secondary Outcomes” section of this chapter. Recruiting a large sample size is 
realistic given the large number of IBD patients seen annually in the specialized Yale IBD clinic. 
 
2.6 Conclusion 
 This review of the relevant literature demonstrates the promise of the routine use of 
PROMs for the care of a variety of chronic conditions based on a wide array of studies which 
exhibit the tool’s ability to improve patient-provider communication, increase recognition of 
symptoms, and improve patient outcomes and symptomatology. With an increasing prevalence 
of IBD in the general population, it is vital to evaluate the efficacy of the use of a PROM in this 
population clinically, as it may be used in lieu of more invasive and expensive disease 
monitoring procedures such as endoscopy. A majority of studies evaluating PROMs employed a 
 29 
parallel design, as it reduces the length of participation and concern for participant attrition, as 
well as eliminates carryover effect implicit to crossover designs. The primary outcome elected 
for this research proposal was health-related quality of life, which was demonstrated throughout 
the studies in this literature review as a statistically significant outcome when implementing a 
PROM and will provide meaningful results, underscoring the utility of routine PROMs in IBD. 
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Chapter Three: Study Methodology 
3.1 Study Design 
We will perform a prospective, parallel design, randomized clinical trial. Participants will 
be recruited using a convenience sampling method and enrolled in the study on a rolling basis. 
They will be randomized to study group using verified computer software and a random number 
generator. Both study and control groups will complete PROMs during the study period, and 
only the intervention group will have the data from these measures shared with their clinician to 
aid in treatment decisions, allowing us to evaluate whether this intervention improves health 
outcomes. Although the nature of our intervention prevents blinding of participants and treating 
clinicians, gastroenterologists interpreting colonoscopy reports and radiologists evaluating 
patient imaging will be blinded to treatment and intervention groups.  
 
3.2 Study Population and Sampling 
The study sample will draw from a population of adults with inflammatory bowel 
diseases including ulcerative colitis, Crohn’s disease, either active or in remission. Both English 
and Spanish speaking subjects will be included, but due to translation constraints patients 
speaking other languages will be excluded. Patients will be recruited from the Yale Inflammatory 
Bowel Disease Clinic at Temple Medical Center in New Haven and Devine Center in North 
Haven. This convenience sampling method has the potential to exclude patients who don’t 
routinely seek medical care, but since the PROM intervention would most benefit a target 
population of motivated patients who routinely seek medical care this limitation is acceptable.  
All patients who meet specific inclusion and exclusion criteria will be eligible to be 
included in the study. Inclusion criteria include patients 18 years of age and older with a 
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diagnosis of inflammatory bowel disease who are undergoing a colonoscopy, MR enterography, 
CT enterography, or capsule endoscopy within 7 days of initial screening and baseline 
questionnaires. Eligible subjects must also have the ability to provide fully informed written 
consent for participation in the study and have the literacy skills necessary to complete the 
questionnaires. Exclusion criteria include concurrent participation in other research studies, 
cognitive impairment by clinical impression, and non-English or non-Spanish speaking patients.  
Table 2. Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
18 years or older Concurrent participation in other 
research studies 
Inflammatory bowel disease 
diagnosis 
Cognitive impairment by clinical 
impression 
Undergoing objective disease 
assessment within 7 days of 
initial clinic assessment 
Neither Spanish nor English 
speaking 
Language proficiency to 
complete questionnaires 
Inability to provide fully 
informed written consent 
 
3.3 Subject Protection and Confidentiality 
IRB approval has been accomplished per Yale IRB Policy 100 PR.1 Review by a 
Convened Institutional Review Board, IRB approval number 200026769. All eligible study 
participants will be required to provide written informed consent. This consent will detail our 
research study’s purpose, procedures, duration, and benefits of participation, as per Yale IRB 
Policy 200 Informed Consent for Human Research. In addition to any risks of participation, this 
consent will lay out alternative treatment strategies including other methods of monitoring IBD 
symptomatology. The consent form will detail patient confidentiality and privacy practices 
including medical records examined by the research personnel or the IRB. Contact information 
for all research personnel including the principal investigator, and details regarding participant 
compensation will also be outlined in the consent form. The form will explain that the 
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participants may discontinue the study at any time. The participants’ disease care will not be 
influenced by dropping out of the study and participants do not need to provide an explanation 
for doing so. Additionally, research personnel may also remove participants from the study at 
their discretion. Any resulting effects from participant discontinuation including changes in 
compensation will be detailed in the consent form. If any new information emerges that has the 
potential to change a participant’s decision to participate in the research study, that information 
will be provided to the subjects immediately and they will be re-consented. The consent form is 
attached in Appendix A.  
The research study will comply with the Health Insurance Portability and Accountability 
Act (HIPAA) regulations including participant recruitment and research protocol. Any personal 
health information will be encrypted. Confidentiality will be ensured by de-identifying all data 
and using password protected encrypted computer servers.  
 
3.4 Recruitment 
Patients will be recruited from the Yale Inflammatory Bowel Disease Clinic at Temple 
Medical Center in New Haven, CT and Devine Center in North Haven, CT. In addition, flyers 
will be posted throughout the New Haven area. A sample flyer is provided in Appendix B. 
Participants will be compensated with a $100 Visa gift card at each of the two visits which will 
also aid recruitment.  
 
3.5 Study Variables and Measures: Primary Outcome, Secondary Outcomes  
In the study intervention group, patients will complete PROM questionnaires prior to 
their appointment (IBD-CQ and PROMIS). The PROMIS questionnaires include the short form 
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measures of Emotional Distress–Depression, Emotional Distress–Anxiety, Fatigue, Sleep 
Disturbance, Pain Interference, and Satisfaction with Participation in Social Roles. The clinician 
will receive the results of the PROM and the patient’s subscores and use this information to 
discuss treatment during the visit.  
The control group will undergo standard of care which will include a thorough baseline 
exam, a therapy plan based on current guidelines.1-3 The control group will complete the same 
IBD-CQ and PROMIS questionnaires prior to each of their clinical appointments. However, the 
results of these questionnaires will not be provided to their clinician.  
 All patients will undergo objective disease assessment within 7 days of completing the 
initial questionnaires depending on the disease locations with either colonoscopy, video capsule 
endoscopic, magnetic resonance enterography (MRE). In addition, within 7 days of completing 
the questionnaires patient will undergo non-invasive inflammatory marker assessment with CRP 
and fecal calprotectin measurements.  
Both intervention and control group patients will have a second clinic visit six months 
after the initial assessment where the questionnaires and clinical assessment measures will be 
repeated. Both participants and providers will rate their satisfaction with the clinical interaction 
after each study visit via a questionnaire. All questionnaires and rating scales used in the research 
study are detailed in Appendix D. 
 The primary outcome will be change in the patients’ health-related quality of life as 
measured by a questionnaire (EQ-5D-5L). Secondary outcomes include change in patient disease 
activity as measured by clinical and endoscopic scoring systems (Mayo UC score for patients 
with ulcerative colitis and the Crohn’s Disease Activity Index (CDAI) for patients with Crohn’s 
disease), discussion of HRQL in the clinic visit, rate of disease exacerbations, patient and 
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provider satisfaction as measured by questionnaire, cost of treatment, and noninvasive measures 
of disease activity such as albumin, fecal calprotectin, C-reactive protein (CRP), and erythrocyte 
sedimentation rate (ESR). 
 This information will be used to determine the extent to which the IBD-CQ aligns with 
traditional measures of disease activity and psychosocial domains. Furthermore, we will assess 
the questionnaires’ responsiveness across the six-month interval between study visits. Overall 
this information will provide guidelines to inform clinical monitoring methods for patients with 
IBD and promote the practice of patient-centered care. 
Figure 1. Proposed Research Study Protocol 
 
 
3.6 Adherence and Adverse Events 
 Information about patient adherence will be easily accessible based on whether or not the 
PROMs are completed. The electronic medical record will be reviewed for evidence of the 
discussion of health-related quality of life during each clinical visit. Providers and patients will 
also indicate whether or not patient health related quality of life was discussed during the visit in 
the short satisfaction questionnaire after each appointment (Appendix D). 
 Participants will be asked during each study visit detailed questions about any adverse 
events they have experienced during the study time period. The phone number of both the 
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research assistant and medical providers will be provided to each participant in case of questions 
or concerns.  
 
3.7 Data Collection 
Disease activity will be measured using standard of care procedures and imaging 
including colonoscopy, CT enterography, MR enterography, or capsule endoscopy. Mucosal 
healing will be assessed via review of the colonoscopy reports by a gastroenterologist blinded to 
the participant’s group allocation. Mucosal healing in Crohn’s disease will be defined as absence 
of ulcerations. Mucosal healing in ulcerative colitis will be defined as Mayo-UC score of 0 or 1. 
Radiologists will be blinded to the patients’ study group and questionnaire responses. Non-
invasive measures of disease activity will be collected via a blood draw including CRP, albumin, 
and fecal calprotectin.  
Data will be abstracted from the medical record for demographics including age, sex, 
body mass index, smoking status, type of inflammatory bowel disease and disease location, 
extent, severity and duration. Previous and current medical and surgical therapy will be noted.  
PROM questionnaire data will include the IBD control questionnaire, the PROMIS 
measures of depression, anxiety, fatigue, sleep, pain, and social functioning, and a health-related 
quality of life questionnaire (EQ-5D-5L). Participants will receive questionnaires via email and 
can respond electronically prior to their study visit. In the event that a patient does not have 
access to the internet, paper copies of the questionnaires will be mailed to their house. 
 
3.8 Sample Size Calculation 
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Our sample size calculation was based on data from a 2016 research study by Basch et al. 
These researchers compared using a PROM prior to clinic appointments for routine cancer 
treatment versus usual care, with a primary outcome measure of proportion of patients with a 
significantly improved health-related quality of life at six months measured by the EuroQol EQ-
5D Index. This trial was subject to significant patient attrition given the population studied, and 
so gives a conservative estimate of the sample size needed for our proposed intervention. Our 
sample size estimation assumes the proportion of patients with improved quality of life scores 
after six months will be 34% and 18% in the intervention and control arms respectively, with an 
absolute difference between groups of 16%. With an alpha of 0.05 and 80% power we calculate a 
sample size of 234 when assuming a 2-tailed hypothesis. Our anticipated attrition rate is 10%, so 
subsequently to compensate for this loss of data, we will recruit a goal of 258 participants. 
Appendix C details the calculations resulting in the required sample size figures.  
 
3.9 Analysis 
Baseline characteristics that could be potential confounders including disease type, 
disease activity or severity, age, sex, disease duration, previous surgery, medication, and location 
of disease will be operationalized as proportions and so will be compared using Chi-Square tests. 
Continuous variables including mean change in health-related quality of life score (primary), 
mean change in clinical disease activity score as measured by CDAI or Mayo-UC Score, and 
mean change in PROM subscores will be represented as means in standard deviation and 
analyzed with student’s t-test. The data will be adjusted for confounders using multiple logistic 
regression analysis. Analysis will be performed under the intention-to-treat model. The 
significance level will be present at P < 0.05.  
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We will assess the underlying structure of the IBD-CQ using principal components 
analysis. We will consider a factor to be relevant if its eigenvalue is greater than 1.1 and has face 
validity.  Questions that have a loading factor of less than 0.4 will be considered for removal. 
Additionally, we will assess the internal consistency of the IBD-CQ using item-by-item 
correlations and Cronbach’s alpha. Correlations less than 0.20 and greater than 0.80 will be 
considered for rejection.  Questions where participants answered the same (greater than 80%) 
will also be considered for rejection as they will not be sensitive enough to discriminate severity. 
We will also aim for a Cronbach’s alpha to be greater than 0.70. We will assess for the 
agreement between the IBD-CQ and clinical disease activity indices using correlations and 
Bland-Altman plots. We will assess the correlations between the IBD-CQ and PROMIS 
questionnaires using Pearson and Spearman’s correlations as appropriate. We will assess the 
responsiveness of the IBD-CQ by repeating the questionnaire six months later and calculating 
the responsiveness ratio.  
We will assess the IBD-CQ ability in predicting mucosal healing by calculating the 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 
likelihood ratio for a positive result (LR+), and likelihood ratio for a negative test result (LR-). 
 
3.10 Timeline and Resources 
In total, the study will span two years, from gathering participants to data collection. 
Participants will be recruited on a rolling basis during the first fifteen months of the study and 
scheduled for an initial visit at their earliest convenience. A six-month follow-up visit will also 
be scheduled for each participant. Data analysis will be performed for an additional two to three 
months after the completion of the study.  
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The protocol for the initial visit will take place at the Yale IBD Center locations at 
Temple Medical Center in New Haven, CT and in North Haven, CT. Each participant will 
complete baseline assessments prior to their visit and within 7 days of objective disease 
assessment. The baseline assessments include the EuroQol questionnaire (EQ-5D-5L), the IBD-
Control Questionnaire, and PROMIS questionnaires of depression, anxiety, fatigue, sleep, pain, 
and social functioning. In the intervention arm, results of these questionnaires will be provided to 
the clinician to inform subsequent treatment. In the control group, the results from the 
questionnaires will not be provided to their treating clinicians. 
The baseline assessment will include a history and physical exam conducted by a 
gastroenterology clinician as well as a colonoscopy, MR enterography, CT enterography, or 
capsule endoscopy depending on what is appropriate for the individual patient. After their initial 
study visit, participants will complete a brief satisfaction questionnaire. Patients will be 
scheduled for a follow-up visit in six months where all assessments will be repeated.  
In order for the proposed study to take place, the required staff will include three 
providers, six nurses, a radiologist, and a research assistant to record and track patient-reported 
data. All study personnel will attend a three-hour training session led by the research assistant 
about the use of PROMs in general, and the specific measures used in the study. The PROM will 
be sent out to participants via email but if necessary, paper copies will be mailed to the 
participants’ homes. Patient parking will either be validated within respective garages or 
reimbursed if appropriate. Compensation for each participant will consist of $100 per visit, paid 
in the form of a VISA gift card. 
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Chapter Four: Discussion and Conclusions 
4.1 Overview  
IBD is a chronic relapsing-remitting disorder with an ever-increasing prevalence that 
requires frequent monitoring. This monitoring process includes invasive and expensive 
procedures such as endoscopy. Unfortunately, endoscopic remission often does not correlate 
with symptomatic remission.1,2 Additionally, even with frequent monitoring, symptoms such as 
fatigue and mental health issues are often not considered in patient treatment regimens or do not 
respond to the IBD medical regimen, despite both the prevalence and severity of these symptoms 
and their paramount importance to patients.3 Gastroenterologists currently seek an improved 
method of disease monitoring that is less invasive, less costly, and more patient-centered. Many 
in the field look towards PROMs to fill this gap.4,5 The use of PROMs has been studied in other 
chronic diseases and they have been shown to be a cost-effective method to improve both 
provider-patient communication and to improve patient symptomatology. Despite their proven 
efficacy in other chronic conditions, researchers have not yet studied the efficacy PROM 
utilization in the population of patients with IBD with a randomized clinical trial. The proposed 
study aims to fill that gap in knowledge by performing a randomized controlled trial to evaluate 
the efficacy of utilizing routine PROMs in clinical practice. Results from this trial will inform 
clinical practice guidelines for monitoring IBD. If successful, this proposed study will provide 
invaluable insight into the care of chronic conditions across a wide spectrum of disorders.  
 
4.2 Advantages and Disadvantages 
This proposal builds on the exhaustive literature exhibiting the utility of PROMs to 
improve patient-provider communication and patient outcomes in a variety of chronic disorders. 
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Our research design furthers this information by evaluating the efficacy of routine use of PROMs 
in the IBD population. The study connects clinical research and real life by evaluating a potential 
tool that will promote a discussion of IBD symptoms that are prevalent and important to the 
population, but often overlooked by healthcare professionals. PROMs are often found to foster 
discussions of quality of life and other symptomatology that is rarely brought up in a clinical 
encounter, but greatly affects our patients’ day-to-day living. In addition, the inclusion of our 
secondary variables will further inform the functionality of the PROM tool for patients with IBD. 
This research is a feasible option to confirm the efficacy of PROM monitoring of IBD, creating a 
more patient-centered approach to managing this chronic condition. 
 There are a few limitations to our study design that are necessary to evaluate our 
hypothesis, and we will take various steps to mitigate each of these disadvantages. The first main 
limitation of the study is its inclusion of a heterogenous study population of patients with both 
ulcerative colitis and Crohn’s disease of varying severities. Although this may introduce 
confounding, including this diverse set of patients is a necessity to allow for generalizability. We 
will also control for disease activity and severity. Randomization and the large sample size 
utilized in the study will minimize potential negative effects from the varied study population. 
Secondly, our intensive regimen of questionnaires introduces the possibility of questionnaire 
fatigue which could result in missing data and information bias affecting the study outcomes. 
Our team chose to employ a relatively short questionnaire, and will send out regular reminders to 
study participants about questionnaire completion which research has shown improves 
compliance.6 Although we considered including serial completion of PROMs every two weeks 
over the six month interval between clinic visits, this was ultimately rejected to minimize the risk 
of questionnaire fatigue. Additionally we will thoroughly explain both patient confidentiality and 
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participation during the consenting process, as misinformation about use of questionnaire data 
has been shown to decrease patient survey completion.7 Furthermore, the nature of our 
intervention renders the blinding of participants and providers to study group impossible, which 
introduces risk of performance bias. Although this limitation is difficult to avoid, our 
intervention will blind participants and personnel to the study hypothesis, reducing this bias. 
Additionally, we will blind outcome assessors when possible, such as reviewers of endoscopy 
and radiology images. Finally, the research study suffers from the assumption that providing the 
results of the PROM to the clinician will result in changes in both the clinician treatment and 
also the subsequent patient outcomes. It remains challenging to measure the direct action taken 
by each clinician. To mitigate this limitation, the medical record for each visit will be reviewed 
to determine whether quality of life was discussed during the visit, which we will use as a proxy 
for the clinician’s actions. 
 
4.3 Feasibility 
Our proposed research study’s timeline spans 24 months, including recruitment, data 
collection, and data analysis. We have allotted fifteen months for rolling participant recruitment, 
an additional six months for the patient follow-up visit, and finally three months of data analysis 
after study completion. This proposed timeline makes our study feasible from a scheduling 
perspective.  
A majority of our intervention involves routine clinical management and tasks that would 
be performed regardless of whether or not we were engaging in this study. The additional 
resources required include various flyers, potential postage fees in the event a patient does not 
have access to the internet, and a research coordinator to ensure recruitment, data collection, and 
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analysis run smoothly. Intervention training of personnel will include a three-hour session 
prepared by the research assistant. The personnel that will need to be trained are nurse 
practitioners, medical doctors, physician assistants, and nurses, ideally all of whom can attend 
the same training session. The research coordinator along with the principal investigator will 
consult with a statistician at Yale School of Medicine for data management and analysis. Overall, 
our proposed research is feasible due to the minimal amount of required resources. 
 With regards to study subjects, the layout of the proposal maximizes patient safety and 
ensures they will be able to complete the intervention seamlessly. The questionnaires used in the 
study are relatively short and completed online at the participant’s convenience prior to the visit. 
Participants will be recruited from current gastroenterology clinics that see a large number of 
patients each year, making recruitment a feasible task. The intervention in our study adds one 
additional clinic appointment to each participant's normal IBD monitoring. To maximize 
compliance of the intervention, subjects will be compensated a $100 Visa gift card at each visit. 
With these provisions our research protocol is feasible within the allotted 24 months, requiring 
minimal funding and resources.  
 
4.4 Clinical Implications and Future Directions 
 Current disease monitoring for IBD is costly and invasive, and also lacks information 
about certain patient symptomatology and the patient perspective. This gap in diagnostic 
monitoring could potentially be filled by utilizing PROMs. A myriad of research has been 
conducted to explore the use of PROMs in multiple different disease cohorts. Despite the depth 
of this research, the efficacy of PROMs in the IBD population has not yet been explored.  
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The use of PROMs has been shown to improve patient-provider communication, refocus 
disease treatment towards patient goals, and improve patient outcomes. Using our particular 
study design, results will be generalizable to patients with varying severities and types of IBD. 
These research results may be incorporated into standard disease management because our 
pragmatic study design closely aligns with real-world clinical practice. Performing the proposed 
research study will have lasting implications for gastroenterology clinic practices, and potentially 
those of other chronic disease specialties.  
Following the completion of this proposed research study, there are a variety of 
subsequent steps that may be taken to further investigate the utility of PROMs in IBD 
management. For example, a major next step could entail using a PROM to identify each 
patient’s personal priority symptom, and focus disease management to target this specific issue, 
as has been done with patients with rheumatoid arthritis.8 In addition, it may be beneficial to 
build on existing research by studying the use of PROMs within cohorts of patients with 
treatment-resistant symptoms to best optimize coordination of care for those that utilize a 
majority of resources.9 Alternatively, PROMs could be used to identify patients whose disease is 
quiescent and do not require frequent follow-up appointments. Finally, there is a potential to 
investigate the combination of weekly patient PROM completion and telemedicine 
appointments, which could allow the provider to adjust treatment with increased frequency. 
While there are many different paths that may be taken after the conclusion of this research, our 
proposed study provides a necessary basis of knowledge for these future investigations. 
 In conclusion, we will determine the efficacy of using a patient-reported outcome 
measure to inform treatment for inflammatory bowel disease. This study will confirm the utility 
of these measures, revolutionizing inflammatory bowel disease treatment, reducing costs and 
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risks associated with disease management, and transitioning the field toward patient-centered 
care, providing implications for other chronic disease management.  
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Appendix A. Participant Consent Form 
PERMISSION FOR PARTICIPATION IN A RESEARCH PROJECT 
310 FR. 2 (2016-1) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
Study Title: Utilizing a patient-reported outcome measure in the management of inflammatory 
bowel disease 
Principal Investigator: Badr Al Bawardy, MD 
Co-Principal Investigator: Jennifer Farren, PA-SII 
Funding Source: Pending 
 
Invitation to Participate and Description of Project 
 
We are inviting you to participate in a research study designed to look at the routine use 
of a patient-reported outcome measure in the care of adults with inflammatory bowel disease. 
Patient-reported outcome measures are questionnaires designed by patients to evaluate important 
subjective symptoms of disease like pain or fatigue. Information from these questionnaires helps 
providers gain valuable insight into patient perspectives. You have been asked to participate 
because you have a diagnosis of inflammatory bowel disease and are 18 years or older. 
Approximately 250 people will participate in this study. 
  
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision.  This permission form 
gives you detailed information about the research study, which a member of the research team will 
discuss with you.  This discussion should go over all aspects of this research: its purpose, the 
procedures that will be performed, any risks of the procedures, possible benefits and possible 
alternative treatments. Once you understand the study, you will be asked if you wish to participate; 
if so, you will be asked to sign this form. 
  
Description of Procedures 
 
If you agree to participating in this study, you will have two clinic appointments at Temple 
Street Medical Center Digestive Diseases department. Much of what is included in each study visit 
is identical to your standard clinical care. In addition to this routine IBD care, you will be asked to 
complete multiple questionnaires. The second variation from your standard appointments is that 
these two visits will be separated by just six months, so you will be seen by your clinician more 
frequently than usual. 
  
Clinic Appointment One: 
      During your first clinic appointment, a member of our research team will complete the 
consenting process with you. Following the consenting procedure, you will be randomized to one 
of two groups: the intervention group or the control group. 
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Randomization means that subjects will be assigned to these groups by chance, without 
the input of a participant or their provider. A computer, not a clinician will decide which of the 
two groups you will be in. The decision will be random and due to chance alone, and not based 
on the patient’s or doctor’s decision. 
Researchers will use a computerized random number generator to put you in either group. 
In the intervention group, participants will complete questionnaires prior to their clinic 
appointment, and results of the questionnaires will be given to their treating provider. In the control 
group, participants will complete the questionnaires prior to their clinic appointment, and their 
clinician will not receive the results of the questionnaires. The questionnaires you will be asked to 
complete are detailed below. 
During the first clinic visit you will also have an appointment with your provider. Your 
provider will ask you details about any recent symptoms you have had and more details about your 
medical history. The provider will also perform a physical exam. Finally, your clinician will use 
the appropriate imaging tool to evaluate your bowels for inflammation. This tool could be a 
colonoscopy, MR enterography, CT enterography, or capsule endoscopy. A trained radiologist will 
evaluate the images from this procedure. 
  
Clinic Appointment Two: 
      Six months later, you will attend your second clinic appointment. The schedule for this 
appointment will be very similar to the first. You will again complete many of the same 
questionnaires and have a similar discussion and physical exam with a provider. Your provider 
will decide whether or not the imaging tools will be necessary for treatment decisions at this 
appointment. Based on this decision you may receive a colonoscopy, MR enterography, CT 
enterography, or capsule endoscopy, and these images will be evaluated by a radiologist. 
  
Questionnaires: 
 All questionnaires will be completed prior to your study visits. The questionnaires will be 
sent to your email address and completed online. If necessary, paper forms of your questionnaires 
will be mailed to your home. 
 For the first study visit, you will be asked to fill out a demographics questionnaire. This 
will ask you to answer questions about your age, gender, occupation, education, household income, 
ethnicity, and marital status. It will take approximately two minutes to complete.  
For both your first and second study visit, you will be asked to complete the IBD-Control 
Questionnaire (IBD-CQ), the Patient-Reported Outcome Measure Information System (PROMIS) 
questionnaires, and the European Quality of Life-Five Dimension (EQ-5D) questionnaire. The 
IBD-CQ will ask you about your satisfaction with your current IBD treatment, and questions about 
your IBD symptoms in the past two weeks. It will take about two minutes to complete. The 
PROMIS questionnaires will ask you questions about your social functioning, anxiety, depression, 
pain, and fatigue. Completing these will take approximately ten minutes. The EQ-5D will include 








First Clinic Appointment  
Questionnaires Time 
Demographics  2 minutes 
IBD-CQ  2 minutes 
PROMIS  10 minutes 
EQ-5D   5 minutes 
Total   19 minutes 
Second Clinic Appointment  
Questionnaires Time 
IBD-CQ  2 minutes 
PROMIS  10 minutes 
EQ-5D   5 minutes 
Total   17 minutes 
 
 
Medical Record Access: 
 If you decide to participate in this study, researchers will also access your medical records 
for information related to your IBD. They will examine your type of IBD (ulcerative colitis or 
Crohn’s disease), the location of your disease, when you were diagnosed, what medications or 
surgeries you have tried for your disease management, any hospitalizations or emergency room 
visits you have had related to your IBD, laboratory results related to your IBD (fecal calprotectin, 
erythrocyte sedimentation rate, c-reactive protein, albumin), and finally any other disease 
diagnoses you have. This information will be used to determine whether these factors alter any of 
the other measurements in the study. 
 
You will be told of any significant new findings that are developed during the course of your 
participation in this study that may affect your willingness to continue to participate. 
 
Risks and Inconveniences 
  
• Questionnaire contents may include personal information related to physical and 
psychological symptoms such as fatigue, anxiety, depression, and sexual dysfunction and 
there is the possible risk of loss of confidentiality.  Every effort will be made to keep your 
information confidential; however, this cannot be guaranteed.  
• The intervention section of this research trial includes provider discussion of 
questionnaire information. As questionnaires do obtain personal information this may 
cause psychological stress. 
• As listed above, the questionnaires will take at most twenty minutes to complete at each 
appointment. This time commitment will be streamlined as much as possible by the 
research coordinator as well as compensated with a $100 Visa gift card. 
• One potential inconvenience is the relatively rapid follow-up appointment which occurs 
six months after the first study visit, which is sooner than the normal standard of care for 
IBD. This inconvenience ideally will be mitigated by the validation of parking and the 




• This clinical trial may modify the standard of care of IBD by integrating patient-reported 
outcome measures (PROMs) into routine clinical monitoring. 
• The results from this study may benefit the population of IBD patients and patients with 
chronic conditions via contributions to scientific literature.  






• Participants will be compensated $100 in the form of a Visa gift card at each study visit. 
Participants that complete only one study visit will receive one $100 Visa gift card. 
Participants that complete both study visits will receive two $100 Visa gift cards. 
• Parking will be reimbursed at each clinic appointment. Transportation costs such as gas, 
tolls, or bus fare will not be compensated for, and each participant is responsible for these 
additional costs.  
• According to the rules of the Internal Revenue Service (IRS), payments that are made to 
you as a result of your participation in a study may be considered taxable income. 
• You will still be responsible for any co-pays required by your insurance company for 
standard treatment. 
 
   
Treatment Alternatives 
 
  Alternative IBD disease monitoring does not include completion of the questionnaires 





Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or State 
law.  Examples of information that we are legally required to disclose include abuse of a child or 
elderly person, or certain reportable diseases.  
All data on study participants will be de-identified, removing names, addresses, phone 
numbers, health insurance information, and all other personal health information. Data will be 
coded by number, and these codes will be stored on password-protected databases on encrypted 
computers. Only the principal investigator and the research assistant will have access to these 
codes. All de-identified data will be stored in locked cabinets. When the results of the research are 
published or discussed in conferences, no information will be included that would reveal your 
identity unless your specific permission for this activity is obtained.  
Representatives from Yale University, the Yale Human Research Protection Program and 
the Yale Human Investigation Committee (the committee that reviews, approves, and monitors 
research on human subjects) may inspect study records during internal auditing 
procedures.  However, these individuals are required to keep all information confidential. 
Information about your study participation will be entered into your Electronic Medical 
Record (EMR). Once placed in your EMR, these results are accessible to all providers who 
participate in the EMR system. Information within your EMR may also be shared with others who 
are appropriate to have access to your EMR (e.g. health insurance company, disability provider). 
 
You do not give up any of your legal rights by signing this form. 
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Voluntary Participation and Withdrawal 
 
You are free to choose not to participate and if you do decide to become a subject you are 
free to withdraw from this study at any time during its course. Refusing to participate or 
withdrawing from the study will involve no penalty or loss of benefits to which you are otherwise 
entitled (such as your health care outside the study, the payment for your health care, and your 
health care benefits). If you decide not to participate or if you withdraw, it will not harm you or 
your relationship with your own doctors or with Yale Digestive Diseases Department or Yale-New 
Haven Hospital. We would still treat you with standard therapy or, at your request, refer you to a 
clinic or doctor who can offer this treatment. Once data for this research has been collected, it will 
be unable to be withdrawn, as it has been anonymized. 
The researchers may withdraw you from participating in the research if necessary. 
Conditions under which subjects might be withdrawn from the research include noncompliance 




We have used some technical terms in this form.  Please feel free to ask about anything 
you don't understand and to consider this research and the permission form carefully – as long as 
you feel is necessary – before you make a decision. 
  
Authorization and Permission 
  
I have read (or someone has read to me) this form and have decided to participate in the project 
described above.  Its general purposes, the particulars of my involvement and possible hazards and 
inconveniences have been explained to my satisfaction.  My signature also indicates that I have 
received a copy of this permission form. 
  
By signing this form, I give permission to the researchers to use and give out information about 
me for the purposes described in this form.  By refusing to give permission, I understand that I 
will not be able to be in this research. 
  
 
Name of Participant: _____________________________                                                              
                                                               
  




                                                                                    
___________________________________________    ___________________ 
Signature of Person Obtaining Permission                       Date 
  
       or 
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___________________________________________    ___________________ 
Signature of Principal Investigator                                   Date 
  
  
If you have further questions about this project or if you have a research-related problem, you 
may contact the Principal Investigator, Dr. Badr Al Bawardy, (555) 555-5555. 
  
If after you have signed this form you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at (203) 432-5919. 
  
If you would like to talk with someone other than the researchers to discuss problems, concerns, 
and questions you may have concerning this research, or to discuss your rights as a research 





Appendix B: Study Flyer 
 
Volunteers Needed for Research Study 
 
What is the study? 
 Researchers at Yale New Haven Health System are running a study to evaluate the 
routine use of a patient-reported outcome measure in the care of adults with inflammatory bowel 
disease. Patient-reported outcome measures are questionnaires designed by patients to evaluate 
important symptoms of disease like pain or fatigue. Information from these questionnaires helps 
providers gain valuable insight into patient perspectives.  
 
Who is eligible? 
 You are eligible for the study if you 
are 18 years or older and have a medical 
diagnosis of inflammatory bowel disease. 
 
What will you be asked to do? 
 Study participants will be asked to 
attend two clinic visits with a YNHH 
gastroenterologist within six months. At 
these visits, they will receive standard 
clinical care and also fill out questionnaires. 
 
Is there compensation for participation? 
 Participants will be compensated up to $100 in the form of a Visa gift card and receive 
parking reimbursement each study visit. 
 
 
If you are interested in participating or have any questions, 





Appendix C: Sample Size Calculation 
Figure 3. Power and Precision Sample Size Calculation 
 
N Per Group above represents the number of participants needed in the intervention and control 
arms of the study. Factoring in an expected ten percent attrition rate, the total sample size 
required in the study is n=258. 
 




Appendix D: Questionnaires 








D.2 Patient Reported Outcomes Measurement Information System (PROMIS) 
D.2.1 PROMIS – Depression 
 
 
D.2.2 PROMIS – Anxiety 
 
 
D.2.3 PROMIS – Fatigue 
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D.2.4 PROMIS – Sleep 
 
 
D.2.5 PROMIS – Pain 
 
 
D.2.6 PROMIS – Social Functioning 
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D.4 Satisfaction Survey – Patient 
Please check one box: Yes No 
Did you discuss your quality of life with your 
provider at your appointment today? 
  
Please rate each of the following: Excellent Good Fair Poor 
The communication with your physician     
The quality of the care you received     
Overall, how would you rate your experience?     








D.5 Satisfaction Survey – Provider 
Please check one box: Yes No 
Did you discuss your patient’s quality of life with 
your patient at the appointment today? 
  
Please rate each of the following: Excellent Good Fair Poor 
The communication with your patient     
The quality of the care you provided     
Overall, how would you rate your experience?     










D.6 Mayo UC Score  
Parameter Score 
A. Stool Frequency 
0 = Normal 
1 = 1-2 stools/day more than normal 
2 = 3-4 stools/day more than normal 
3 = 5 or more stools/day than normal 
B. Rectal bleeding 
0 = None 
1 = Visible blood with stool less than half the time 
2 = Visible blood with stool half of the time or more 
3 = Passing blood alone 
C. Mucosal appearance at endoscopy 
0 = Normal or inactive disease 
1 = Mild disease (erythema, decreased vascular pattern, 
mild friability 
2 = Moderate disease (marked erythema, absent 
vascular pattern, friability, erosions) 
3 = Severe disease (spontaneous bleeding, ulceration) 
D. Physician rating of disease activity 
0 = Normal 
1 = Mild 
2 = Moderate 
3 = Severe 
Full Mayo Index Score = A + B + C + D 




Interpretation of Mayo Index Scores 
Full Mayo Index Score Score 
  Higher = more severe 0-12 
Partial Mayo Index Score  
  Remission 0-1 
  Mild 2-4 
  Moderate 5-6 





D.7 Crohn's Disease Activity Index (CDAI)  
Parameter Score Weight 
P1. Number of liquid or soft stools 
(evaluated within a week) 
0, 1, or 2 2 
P2. Daily abdominal pain (evaluated within 
a week) 
0 = none 
1 = mild 
2 = moderate 
3 = severe 
5 
P3. Patient wellbeing (evaluated within a 
week) 
0 = very well 
1 = slightly below par 
2 = poor 
3 = very poor 
4 = terrible 
7 
P4. Complications 
0 = No 
1-6 = Yes (drop-down menu with multiple 
selections, each complication is counted as one 
point) 
     Arthralgia or arthritis 
     Iritis or uveitis 
     Erythema nodosum, pyoderma gangrenosum, or 
aphthous ulcer 
     Fissures, anal abscesses, or fistulas 
     Other fistulas 
     Fever during the previous week 
20 
P5. Use of diphenoxylate or opiates as anti-
diarrheal 
0 = No 
1 = Yes 
30 
P6. Abdominal mass 
0 = No 
0.4 = Dubious 
1 = Yes 
10 
P7. Hematocrit 
0-100% = difference between standard value and 
current value 
(# = Standard – Current) 
Standard Value: 47 for males, 42 for females 
6 
P8. Body weight 
-10-100% = the percent change in weight compared 
to the standard weight 
(# = 100 x ((Standard-Current)/Standard)) 
Standard Value: (height in m)2 x 22.1 for males, 
(height in m)2 x 20.8 for females 
In case of excessive negative change, the maximum 
score is -10 points  
 
Summary Score (CDAI) = (P1 x 2) + (P2 x 5) + (P3 x 7) + (P4 x 20) + (P5 x 30) + (P6 x 10) + (P7 x 6) + P8 
 
Interpretation of CDAI Summary Scores 
Severity Score 
Remission ≤150 
Mild activity 151-219 
Moderate activity 220-450 
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